UCL researchers develop an AI tool to predict brain tumor MRI enhancement, reducing the need for gadolinium contrast agents.
Key Details
- 1AI tool designed to predict which brain tumor areas would enhance with contrast on MRI.
- 2Developed by a team at University College London (UCL).
- 3Tool aims to minimize unnecessary exposure to gadolinium-based contrast agents (GBCAs).
- 4GBCAs can accumulate in the body and are a concern for patients with kidney disease, allergies, or those needing frequent follow-ups.
- 5Model validated to work from non-contrast MRI sequences alone.
Why It Matters
Reducing routine use of GBCAs may lower patient risk, especially among those with renal impairment or allergies, while still enabling accurate tumor monitoring. AI-driven solutions like this offer a path toward safer and more efficient MR imaging protocols in oncology.
Source
Radiology Business
Related News
•Radiology Business
Rad Partners Wins $1.29M FDA Grant for AI Radiology Report Evaluation Study
Cognita Imaging, part of Rad Partners, has received a $1.29M FDA grant to develop a new framework using large language models (LLMs) to evaluate AI-generated radiology reports.
•Radiology Business
Real-World Study: Radiology AI Best in Emergency and Inpatient Settings
A commercial AI tool for intracranial aneurysm detection outperformed in inpatient and emergency settings but yielded limited benefits for outpatients in a major health system study.
•Radiology Business
New Rubric Enhances Safety of AI-Generated Radiology Summaries
Researchers developed a five-factor rubric to assess the safety and quality of AI-generated, patient-friendly radiology report summaries.